Adamas Up 40% After FDA Approval Of Gocovri

Adamas Pharmaceuticals Inc ADMS shares are trading higher by $6.00, or 42 percent, at $20.23 in Friday's session.

The catalyst for the rally is the FDA approval of GOCORVI for the treatment of Parkinson's disease.

See Also: Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments

After a much higher open, Adamas continued in that direction until peaking at $21.44. That marks the first time the stock has traded in the $20.00 handle since January 2016.

Profit-takers have come in and the stock has drifted lower. As of Noon EST, the low for the session stands at $19.71, but it has rebounded and has been consolidating in the lower $20.00 handle.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!